These studies supported the development of a new molecular classification of IDH1-R132H and loss of ATRX, in that the clinical characteristics and prognosis of patients with grade II/III glioma and GBM are not accurately reflected by histological classifications [8, 9, 11–13]. Here, IDH1 is linked to glioblastoma.